ARAF is altered in 1.49% of schwannoma patients [2].

ARAF is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains ARAF status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains BRAF status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

IDH1 is altered in 1.45% of schwannoma patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and schwannoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and schwannoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAP3K1 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAP3K1 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF1 is altered in 1.49% of schwannoma patients [2].

NF1 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

NF2 is altered in 52.24% of schwannoma patients [2].

NF2 is an inclusion eligibility criterion in 5 clinical trials for schwannoma, of which 2 are open and 3 are closed. Of the trials that contain NF2 status and schwannoma as inclusion criteria, 2 are early phase 1 (1 open) and 3 are phase 2 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

SRC is an inclusion eligibility criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains SRC status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].